Tenax Therapeutics (TENX) Return on Capital Employed (2011 - 2026)
Tenax Therapeutics recorded quarterly Return on Capital Employed of 58.56% in Q1 2026, little changed quarter-over-quarter from 58.51% in Q4 2025, and down 3207.0% year-over-year from 1.88% in Q1 2025.
Tenax Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 58.56% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3207.0% year-over-year to 58.56%; the TTM figure through Mar 2026 stood at 58.56% (down 3207.0% YoY), while the FY2025 annual figure was 60.43%, down 2105.0% from the prior year.
- Return on Capital Employed came in at 58.56% for Q1 2026 at Tenax Therapeutics, roughly flat from 58.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 496.95% in Q4 2022 to a low of 1861.13% in Q1 2022.
- A 5-year average of 235.56% and a median of 48.33% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 258417 bps in 2022 and surged 194246 bps in 2023, its largest moves.
- Tenax Therapeutics' Return on Capital Employed stood at 496.95% in 2022, then slumped by 128 bps to 137.96% in 2023, then surged by 85 bps to 20.84% in 2024, then tumbled by 181 bps to 58.51% in 2025, then decreased by 0 bps to 58.56% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 58.56%, 58.51%, and 48.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | -58.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.56% |
| Dec 31, 2025 | -58.51% |
| Sep 30, 2025 | -48.33% |
| Jun 30, 2025 | -32.93% |
| Mar 31, 2025 | -26.50% |
| Dec 31, 2024 | -20.84% |
| Sep 30, 2024 | -48.11% |
| Jun 30, 2024 | -172.16% |
| Mar 31, 2024 | -123.91% |
| Dec 31, 2023 | -137.96% |
| Sep 30, 2023 | 35.33% |
| Jun 30, 2023 | 37.36% |
| Mar 31, 2023 | 81.33% |
| Dec 31, 2022 | 496.95% |
| Sep 30, 2022 | -917.58% |
| Jun 30, 2022 | -1,148.98% |
| Mar 31, 2022 | -1,861.13% |
| Dec 31, 2021 | -555.85% |
| Sep 30, 2021 | 729.09% |
| Jun 30, 2021 | 1,207.78% |
| Mar 31, 2021 | 723.04% |
| Dec 31, 2020 | 169.74% |
| Sep 30, 2020 | -125.31% |
| Jun 30, 2020 | -208.45% |
| Mar 31, 2020 | -206.63% |
| Dec 31, 2019 | -188.56% |
| Sep 30, 2019 | -76.65% |
| Jun 30, 2019 | -67.80% |
| Mar 31, 2019 | -56.70% |
| Dec 31, 2018 | -88.04% |
| Sep 30, 2018 | -216.00% |
| Jun 30, 2018 | -183.35% |
| Mar 31, 2018 | -130.62% |
| Dec 31, 2017 | -97.54% |
| Sep 30, 2017 | -524.30% |
| Jun 30, 2017 | -400.28% |
| Mar 31, 2017 | -338.50% |
| Dec 31, 2016 | -181.34% |
| Sep 30, 2016 | -12.24% |
| Apr 30, 2013 | -431.64% |
| Jan 31, 2013 | -447.05% |
| Oct 31, 2012 | -203.85% |
| Jul 31, 2012 | -1,172.11% |
| Apr 30, 2012 | -435.11% |
| Jan 31, 2012 | 615.43% |
| Oct 31, 2011 | 30.63% |
| Jul 31, 2011 | 223.95% |